Status:
COMPLETED
Low Dose Ketamine and Acute Pain Crisis
Lead Sponsor:
Rhode Island Hospital
Conditions:
Sickle Cell Crisis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
BACKGROUND: Current treatment standard for acute pain crisis in sickle cell disease (SCD) is largely supportive care: opioid analgesics, hydration, oxygen, and blood transfusion. Sickle cell disease ...
Detailed Description
Current treatment standard for acute pain crisis in sickle cell disease (SCD) is largely supportive care: opioid analgesics, hydration, oxygen, and blood transfusion. Sickle cell disease (SCD) is a ch...
Eligibility Criteria
Inclusion
- All English-speaking adult patients \>=18yrs old patients presenting with acute pain crisis
Exclusion
- Inability to provide consent,
- Allergy to ketamine
- Pregnant or breastfeeding. W
- Signs and symptoms of intracranial hypertension
- Neurologic deficits
- Headache only
- Temperature \>102F
- Sustained blood pressure \>=180/110
- Sustained heart rate \>130
- Current priapism
- Patients requiring a blood transfusion at the time of acute presentation
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04330183
Start Date
July 1 2020
End Date
October 1 2021
Last Update
December 23 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Rhode Island Hospital
Providence, Rhode Island, United States, 02905
2
The Miriam Hospital
Providence, Rhode Island, United States, 02906